Affordable Needle-Free Screening With Instant Results

Addressing a Global Health Crisis

Diabetes mellitus (DM) is a worldwide epidemic affecting 537 million adults, with an equal number living undiagnosed. This chronic metabolic condition manifests in several forms:

• Type 1 Diabetes (T1DM): Caused by autoimmune β-cell destruction, leading to absolute insulin deficiency
• Type 2 Diabetes (T2DM): Characterized by progressive loss of β-cell insulin secretion with insulin resistance
• Gestational Diabetes Mellitus (GDM): Diagnosed during pregnancy
• Other specific types: Including monogenic diabetes syndromes, exocrine pancreas diseases, and drug-induced diabetes

Early detection is crucial, but current diagnostic methods often miss asymptomatic individuals, allowing comorbidities to progress unnoticed.

Diabetes is typically diagnosed based on plasma glucose criteria:

• Fasting plasma glucose (FPG)
• 2-h postprandial plasma glucose (2-h PPG) during a 75-g oral glucose tolerance test (OGTT)
• Glycated haemoglobin (HbA1c) criteria

While these tests are reliable for identifying high-risk individuals, they fall short in detecting asymptomatic cases, leading to delayed diagnoses and increased health burdens.

Introducing the Glyconics-DS System, an innovative diabetes screening tool designed to assess glycated keratin levels in fingernails as an indicator of diabetes risk.

Key Components:

1. Glyconics-DS device: A hand-sized near-infrared diffuse reflectance (NIR) spectrometer
   • Reusable and software-driven
   • Noninvasive and nonsterile
2. Glyconics-DS Cradle: An interoperable accessory for precise device positioning
   • Ensures accurate placement above the patient’s nail
   • Guarantees safe operation without pressure on the nail or the user’s hands
3. Glyconics mobile application: For result display to healthcare professionals

Advantages:

• Non-invasive fingernail scanning
• No needles or blood samples are required
• Quick and uncomplicated risk assessment
• Cloud-based predictive algorithm
• Portable and user-friendly design

The Glyconics-DS System leverages the formation of Advanced Glycation End-products (AGE) in sustained hyperglycaemia.

By analysing glycated keratin in fingernails, our device provides a robust biomarker for diabetes screening, offering an alternative to traditional blood-based tests like HbA1c.

The Glyconics-DS System is designed for use by trained healthcare professionals to screen:

• Adults (≥18 years) with unknown diabetes status
• Individuals with at least one visually assessed undamaged, intact fingernail (preferably middle)

Important Note: The Glyconics-DS System is not intended for diabetes diagnosis or direct clinical decision-making. It serves as a screening tool to inform healthcare professionals about diabetes risk.

Our comprehensive user manual ensures proper device operation, maintenance, and troubleshooting. It provides detailed instructions on:

• Device setup and initialisation
• Proper scanning technique for optimal results
• Interpretation of screening results
• Device maintenance and cleaning procedures
• Troubleshooting common issues
• Safety precautions and contraindications

Download the full manual here for detailed instructions.

Important Note: Only use the Glyconics-DS System if you have completed this training.

While the Glyconics-DS System is safe for external use, certain conditions may affect results:

• Medical conditions impacting blood-based glycemia assessment (e.g., severe anaemia, hemoglobinopathies)
• Structural nail deviations (e.g., nail dystrophy, severe infections)
• Use of systemic or topical medications affecting nail structure or HbA1c accuracy

Important Note: Please consult the user manual for a complete list of contraindications.

The Glyconics-DS System has the potential to revolutionise diabetes screening in various clinical settings:

1. Primary Care: Enables quick, non-invasive screening during routine check-ups
2. Community Health Programs: Facilitates large-scale screening initiatives in underserved areas
3. Occupational Health: Supports workplace wellness programs and early intervention strategies
4. Pharmacies: Allows for convenient screening in accessible community locations

By providing a user-friendly, non-invasive screening method, Glyconics-DS aims to:

• Increase early detection of diabetes and prediabetes
• Reduce the burden of undiagnosed cases
• Facilitate timely intervention and management
• Potentially decrease long-term complications and healthcare costs

Experience the power of advanced infrared technology in diabetes risk assessment. The Glyconics-DS System offers a quick, painless, and innovative approach to identifying individuals at risk, potentially improving early intervention and management of this global health concern.

We value your inquiries and feedback. Please find our contact information below:

Correspondence Address:

The Grosvenor House
Basing View
Basingstoke, RG21 4HG

Customer Support:

For general inquiries and assistance, please email: info@glyconics.com

Safety Reporting:

To report any safety concerns or incidents, please email: safety@glyconics.com

Technical Support:

For device-related issues or troubleshooting, contact: support@glyconics.com